CHARLOTTE, N.C., Sept. 4, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 14 th Annual Rodman & Renshaw Global Healthcare Investment Conference at 3:40 PM ET on Monday, September 10, 2012 at the Waldorf Astoria in New York City .
Joseph G. Oliveto, Chelsea's Interim Chief Executive Officer will provide a corporate update and an overview of the Northera™ (droxidopa) development program.
Mr. Oliveto's presentation will be webcast live and archived for 30 days on Chelsea's website, www.chelseatherapeutics.com .About Chelsea Therapeutics Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system disorders. Chelsea is currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a novel, late-stage, orally-active therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information about the Company, visit www.chelseatherapeutics.com
CONTACT: Investors: Michelle Carroll/Susan Kim Argot Partners 212-600-1902 email@example.com firstname.lastname@example.org Media: David Pitts Argot Partners 212-600-1902 email@example.com